SEC Comment Letter for Entero Therapeutics, Inc. (GRDX) (CIK 0001604191) (GRDX) — Nov 6, 2019

Entero Therapeutics, Inc. (GRDX) (CIK 0001604191)
Date: Nov. 6, 2019 · CIK: 0001604191 · Accession: 0000000000-19-015267

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-37853

Date

November 6, 2019

Author

Not clearly detected

Form

UPLOAD

Company

Entero Therapeutics, Inc. (GRDX) (CIK 0001604191)

Letter

November 6, 2019 James Sapirstein Chief Executive Officer AzurRx BioPharma, Inc. 760 Parkside Avenue Downstate Biotechnology Incubator, Suite 304 Brooklyn, NY 11226 Re:AzurRx BioPharma, Inc. Preliminary Proxy Statement on Schedule 14A Filed October 28, 2019 File No. 001-37853 Dear Mr. Sapirstein: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jessica R. Sudweeks, Esq.

Show Raw Text

November 6, 2019
James Sapirstein
Chief Executive Officer
AzurRx BioPharma, Inc.
760 Parkside Avenue
Downstate Biotechnology Incubator, Suite 304
Brooklyn, NY 11226
Re:AzurRx BioPharma, Inc.
Preliminary Proxy Statement on Schedule 14A
Filed October 28, 2019
File No. 001-37853
Dear Mr. Sapirstein:
            We have completed our review of your filing.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Jessica R. Sudweeks, Esq.

SecProbe.io